Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.38 |
| ▸ | TERT | O14746 | 5/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13525340 | 0.92 | — | — | |
| SCHEMBL3167533 | 0.88 | SCN5A (0.35) | — | |
| SCHEMBL3161034 | 0.87 | LTA4H (0.35) | LTA4H | |
| SCHEMBL3170517 | 0.86 | SCN5A (0.35) | — | |
| SCHEMBL13525335 | 0.86 | SCN5A (0.37) | — | |
| SCHEMBL3167552 | 0.85 | SCN5A (0.37) | — | |
| SCHEMBL3166761 | 0.84 | — | — | |
| SCHEMBL3160616 | 0.84 | SCN5A (0.34) | — | |
| SCHEMBL3166633 | 0.83 | — | — | |
| Trifluoroacetic Acid SCHEMBL3160635 | 0.82 | LTA4H (0.33) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230084521-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2023-03-16 | — | — | US | claimed |
| US-7645792-B2 | Prodrugs of propofol, compositions and uses thereof | XENOPORT, INC. (US) | 2010-01-12 | — | — | US | claimed |
| US-7241807-B2 | Prodrugs of propofol, compositions and uses thereof | XENOPORT, INC. (US) | 2007-07-10 | — | — | US | claimed |
| US-20060041011-A1 | Prodrugs of propofol, compositions and uses thereof | XENOPORT, INC. | 2006-02-23 | — | — | US | claimed |
| WO-2006017351-A1 | PRODRUGS OF PROPOFOL, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2006-02-16 | — | — | WO | claimed |
| EP-4288062-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | Epalex Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230277567-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2023-09-07 | — | — | US | disclosed |
| US-11628178-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2023-04-18 | — | — | US | disclosed |
| US-20230084521-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2023-03-16 | — | — | US | disclosed |
| US-7645792-B2 | Prodrugs of propofol, compositions and uses thereof | XENOPORT, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090005352-A1 | Prodrugs of Propofol, Compositions and Uses Thereof | XENOPORT, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-7241807-B2 | Prodrugs of propofol, compositions and uses thereof | XENOPORT, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-20060041011-A1 | Prodrugs of propofol, compositions and uses thereof | XENOPORT, INC. | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041011-A1 | Prodrugs of propofol, compositions and uses thereof | CYP2C19, CYP3A5, CYP3A4 | MMP2 2949/4885GNAI3 727/4885GNAO1 572/4885 |
| US-20090005352-A1 | Prodrugs of Propofol, Compositions and Uses Thereof | CYP2C19, CYP3A5, CYP3A4 | MMP2 2949/4885GNAI3 727/4885GNAO1 572/4885 |
| US-11628178-B2 | Fospropofol methods and compositions | FOS, FOSB, PFAS | MMP2 4009/4885GNAI3 1371/4885GNAO1 1101/4885 |
| US-20230277567-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | FOS, FOSB, PFAS | MMP2 4009/4885GNAI3 1371/4885GNAO1 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.